Business
Vistagen Appoints Nick Tressler as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., December 01, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025.
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/dcb7cc85676050673c0653eebab7e57b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pZz_TkRXmU0owTXpXlZKCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/dcb7cc85676050673c0653eebab7e57b","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uR9Vfcc6kI2q1NPA2.r0_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/dcb7cc85676050673c0653eebab7e57b","width":1200,"height":325}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., December 01, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025.","length":404,"tagName":"p"},{"type":"text","content":""I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the positive impact he will have throughout our company as we continue building momentum and delivering on our vision."","length":492,"tagName":"p"},{"type":"text","content":"Mr. Tressler brings over 20 years of financial leadership experience in the life sciences industry guiding companies through pivotal growth and transformation. Most recently, he served as CFO of DYNEX Technologies, and before that, he was the CFO at American Gene Technologies, International, and Senseonics Holdings, Inc. (Nasdaq: SENS). Mr. Tressler has also held senior finance roles at several biopharmaceutical companies, including Sucampo Pharmaceuticals, acquired by Mallinckrodt in 2018, and MedImmune LLC, acquired by AstraZeneca PLC (Nasdaq: AZN) in 2007. Mr. Tressler holds an M.B.A. from Johns Hopkins Univ...